Mark Erlander

Mark Erlander

Plus aucun poste en cours

Fortune : 46 514 $ au 31/05/2026

66 ans
Consumer Services
Health Technology
Health Services

Profil

Mark Erlander worked as an Assistant Professor at The Scripps Research Institute from 1991 to 1994.
From 1994 to 2000, served as Principal at Johnson & Johnson.
Held the position of Chief Scientific Officer at Arcturus Studios Holdings, Inc. between 2000 and 2008.
Worked as Chief Scientific Officer at Biotheranostics, Inc. from 2008 to 2013.
Served as Chief Scientific Officer at Gensignia Life Sciences, Inc. from 2013 to 2014.
From 2020 to 2026, was Chief Executive Officer & Director at Cardiff Oncology, Inc. Education includes a doctorate from the University of California, Los Angeles, graduate studies at Iowa State University, and undergraduate studies at the University of California, Davis.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
20/04/2026 24 481 ( 0,04 % ) 46 514 $ 31/05/2026

Anciens postes connus de Mark Erlander

SociétésPosteFin
CARDIFF ONCOLOGY, INC. Directeur Général 27/01/2026
Directeur Technique/Scientifique/R&D 01/03/2014
Directeur Technique/Scientifique/R&D 01/02/2013
Directeur Technique/Scientifique/R&D 01/01/2008
JOHNSON & JOHNSON Corporate Officer/Principal 01/01/2000
Voir l'expérience en détail de Mark Erlander

Formation de Mark Erlander

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

75

Relations au 1er degré

9

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées9

Health Technology

Health Services

Consumer Services

Consumer Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Technology Services

  1. Bourse
  2. Insiders
  3. Mark Erlander
🔇